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Bone marrow sparing RT in era of immunotherapy
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Jolanta Łuniewska-Bury3, Jacek Fijuth1 
Recent advances in the field of immunotherapy have changed the perception of cancer treatment to complex model 
with host immunity in the spotlight. Potential synergy of immunotherapy drugs [aiming cytotoxic T cell antigen 4 
(CTLA-4) or programmed cell death-1/ligand (PD-1/PD-L1)] and radiotherapy (RT) have established basis for ongo-
ing clinical trials testing combined treatment. It was shown that complete blood cell counts (CBC) parameters may 
correlate with cancer survival, toxicity and outcomes of treatment. Therefore, reduction of hematologic toxicity of 
cancer treatment may gain in significance. Modern dose delivery techniques compromise dose reduction in critical 
organs (like bone marrow — BM) with adequate irradiation of target volumes. In addition, usage of modern imaging 
like positron emission tomography (PET), magnetic resonance imaging (MRI) allows to divide the volume of BM to 
active and inactive one.
In this review, we discuss the synergy of RT and immunity and techniques of Bone Marrow Sparing RT (BMS-RT).
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Introduction 
The twentieth century was a period of great discoveries 
in oncology. The first major successes were associated 
with local treatment of solid tumors. The development 
of surgical techniques and discovery of ionising radiation 
were the main factors that enabled successful treatment 
of patients with locally advanced stages of cancer. Exten-
sive local treatment has been replaced with more precise 
one with adjuvant treatment, a good example can be 
the treatment of breast cancer [1, 2]. In the recent years, 
alongside surgery, chemotherapy and radiotherapy (RT), 
immunotherapy has become recognizable as the fourth 
pillar of oncology with possible synergy with RT [2, 3]. 
The idea of significant role of immunity in cancer is not 
new. Injections of malignant cells to prevent cancer were 
described as early as in 1777, than they were clinically inve-
stigated in sarcomas with cure rate of 10% in year 1891 [4]. 
Immunotherapy has a history of ups and some spectacular 
downs, such as disappointing results of vaccines against 
cancer cells [4]. In recent years conventional perception of 
tumor “detached from microenvironment” have changed 
to more complex model where radiosenstivity of cells is 
affected by host immunocompetence [5]. Anti-tumor spe-
cific host immunity can be enhanced by cancer cell death, 
induced by radiation [2]. Studies concerning combined RT 
with checkpoint blockade immunotherapy have cast new 
light on the subject [2]. Moreover, efforts are being made 
to explain how anticancer treatment can harm patient 
immunology system [6, 7]. In view of the fact that immu-
notherapy relies on host’s own immunity, the prevention of 
hematologic toxicity (HT) due to cancer treatment seems 
to be important. One of the investigated approaches to 
reduce RT related HT is bone marrow sparing RT (BMS-RT). 
Highly conformal RT techniques allow to reduce radiation 
dose in bone marrow (BM) without deterioration of dose 
coverage of target structures [8]. Most of active bone mar-
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row in adults is localized in pelvis [8]. Highly conformal RT 
techniques are not routinely used for all cancers in this 
region, because of scarcity of clinical trials and concerns 
about target movement [9]. In this review, we discuss ad-
vantages of different kinds of BMS-RT. Recent discoveries 
in immunotherapy are also briefly reviewed.
RT and immunity 
Host immune status is believed to influence the natural 
history of cancer [10, 11]. The immunoediting hypothesis 
along with possible stages of cancer cells existence (elimi-
nation, equilibrium, dormancy, escape) show role of host 
own immunity in cancer survival [12, 13]. There is a substan-
tial body of evidence that late recurrences and long term 
survival depend on immune mediated equilibrium [13]. 
Lymphocytes are involved at various steps of host response 
to cancer, and may modulate response to treatment [14, 15]. 
Lymphopenia and decreased ratio of lymphocytes to neu-
trocytes or platelets might be prognostic factor in survival 
for various cancer types [16–19]. Moreover pretreatment 
lymphopenia was proposed to predict survival and early 
death after chemotherapy for breast cancer, lymphomas and 
sarcomas [20, 21]. d’Engremont et al. found pre- and post-
-operative lymphopenia to be an independent prognostic 
factor for survival in patients with pancreatic cancer [22]. 
Similarly, severe lymphopenia was shown to predict poor 
survival in patients after chemoradiotherapy (CRT) for ce-
rvical cancer [23]. Baseline complete blood count cells (CBC) 
predict occurrence of HT during whole pelvis RT (WPRT) for 
prostate cancer [24].
The balance between tumor induced immuno-sup-
pression and immuno-enhancing pathways is crucial in 
cancer survival [14]. Moreover, duality of effect (pro and 
anticancerous) is observed in cancer therapy [25]. In unfa-
vorable situation eradication of tumor cells may be nullified 
by host immunity reactiveness, repopulation and malignant 
clones selection [25]. Radiotherapy or CRT was generally 
considered to be immunosuppressive because of observed 
reduction in blood cell counts [2, 26]. Ionizing radiation 
causes DNA damage thus rapidly dividing cells such as 
neoplasm cells, leucocytes and lymphocytes with its pre-
cursors are prone to RT [3, 26]. Drop in CD8+ and CD4+ 
lymphocytes with increased expression of programmed 
cell death-1 (PD-1) receptors were observed during CRT 
of cervical cancer [27]. Authors concluded that CRT sup-
presses immune system and thus combination of RT and 
immunotherapy could be difficult [27]. 2-D planning RT 
and imperfect imaging techniques required large treatment 
field. This in turn causes unintended irradiation of healthy 
tissues including bone marrow, blood pool, local lymphatic 
system [2, 3]. With the development of modern precise 
treatment the immune-compromising effect of RT can be 
significantly reduced [2, 3].
The synergy between RT and immunity must be con-
sidered in broad context. Lee et al. demonstrated that tu-
mor control was different in immunocompetent and nude 
mice (without T CD8+ and some B lymphocytes) by abla-
tive RT [15]. In this melanoma model regression depended 
on T CD8+ lymphocytes [15]. The body of preclinical data 
and casuistic reports suggest that RT has the potential to 
enhance response to immunotherapy and vice versa im-
munotherapy can modify tumor microenvironment and 
radiosensitivity of cancer cells [28]. Cytotoxic T cell antigen 
4 (CTLA-4) and PD-1/PD-L1 checkpoints are significant mo-
lecular brakes which prevent T cells from hyperactivity and 
in patients with cancer can suppress natural host defense 
against cancer [10, 29]. In addition to promising results of 
immunotherapy as single method, the results of animal 
based studies show the synergy between RT and inhibitors 
of CTLA-4 and PD-1/PD-L1 checkpoints [30, 31]. Anti PD-1/ 
/PD-L1 checkpoints drugs enable T cells to influence tumor 
microenvironment and to decrease the number of sup-
pressive cells [14]. Improved survival or local control was 
demonstrated for combined radiotherapy and anty PD-1/ 
/PD-L1 treatment for gliomas, melanomas, breast carcino-
mas animal models [32, 33]. Preclinical studies provided 
the evidences for more than 20 ongoing trials testing the 
effect of combined immuno-radiotherapy treatment [34]. 
The abscopal effect (AE) (regression of cancer lesions 
outside of RT filed), although described in 1950’s, was po-
stulated to be immune mediated five decades later by De-
maria et al. [35, 36]. This phenomenon, rarely observed in 
clinical routine when RT is administrated alone, has recently 
become more commonly reported when RT is combined 
with immunotherapy [14]. Postow et al. and then others 
reported AE in melanoma and non-small cell lung cancer 
patients treated with Ipilimumab and RT [37–41]. Golden et 
al. conducted trial reporting occurrence of AE in 26,8% of 
patients with oligometastatic breast, lung and thymic cancer 
treated with granulocyte-macrophage colony-stimulating 
factor and palliative regiment of RT [42]. AE was observed 
in 52% of patients treated with palliative RT after progres-
sion on Ipilimumab [38]. Authors concluded that AE may 
correlate with prolonged overall survival [38].
Both immunosuppressive and immunenhancing me-
chanism of RT and immunity have been comprehensively 
reviewed by Weichselbaum et al. [14]. Equilibrium of these 
effects is believed to have huge impact on cancer treatment 
success [14]. Various groups of mechanisms how irradiation 
influences cancer cells and microenvironment have been 
described in details [14]. The aforementioned preliminary 
data suggest that radiotherapy and immunity can influence 
cancer natural history. Taking into account interaction be-
tween RT and host immunity (especially lymphocyte status), 
therapeutic strategies to preserve patient natural immunity 
during cancer treatment may gain in significance. 
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Bone marrow sparing RT
Radiotherapy has undergone remarkable transforma-
tion in the field of treatment precision [43]. Progress from 
2D radiotherapy and imaging to image guided, dynamic 3D 
irradiation techniques and molecular imaging, enables us to 
spare organs at risk (OAR) and escalate radiation dose inside 
target volumes [44, 45]. BMS-RT advantages should be the 
most appreciated in large treatment fields encompassing 
axial skeleton (skull, spine, sternum, clavicles, scapulas, pe-
lvis) where the vast majority of red (active) bone marrow 
is localized in adults [46]. Approximately half (40–50%) of 
bone marrow is localized in pelvic region [47, 48]. Majority of 
available clinical data describes the application of intensity 
modulated radiation therapy (IMRT) for BMS-RT for prostate, 
cervical, rectum, anal cancers [47, 49–58]. In macroscopic 
cervical and rectum cancer dynamic irradiation techniques 
are still not first-line treatment options due to concerns over 
internal organ motion [8, 9, 59]. They should be applied with 
caution and accompanied with image guidance when signi-
ficant dosimetry advantage in OAR is achieved [9, 48, 59]. 
National Comprehensive Cancer Network (NCCN) guidelines 
indicate that IMRT should only be administrated for unique 
clinical situation like reirradiation or inside clinical trials [9]. 
Limited data regarding BMS-RT are available for esophageal 
and gastric cancer [60, 61]. Two main approaches for BMS-RT 
are: 1) dose reduction in total bone marrow (BMtot)-deline-
ated as entire bone volume near planning target volume and 
2) division of bone marrow on basis of functional imaging 
to red (active) bone marrow (BMact) and yellow (inactive) 
bone marrow (BMinact).
Total bone marrow sparing RT in treatment area
In the era of RT used as a single method of treatment, 
HT was not clinically significant sequalae, attention was 
focused on gastrointestinal or urinary toxicity [48, 62]. In 
the recent two decades when CRT for cervical, rectum, anal, 
gastric cancer have become widespread, HT is one of the 
most common side effects of combined treatment [63]. IMRT 
was found to reduce HT/dose to BM, even without dose 
constrains for BMtot in IMRT in CRT for cervical, anal and 
rectal cancer [53, 62, 64, 65]. IMRT was reported to reduce 
low (not confirmed by all authors) and high doses to BM 
volume [53, 65–68]. IMRT due to higher amount of leakage 
dose may affect distant sites of BM [69]. Differences in dose 
distribution in BM were observed mostly in iliac BM [62]. 
With dose restrictions for BMtot, in IMRT planning, reduction 
in doses delivered to BMtot can be more significant  [67, 
70–72]. In recent analysis Mell et al. has suggested that pos-
itron emission tomography (PET) guided IMRT can further 
decrease the incidence of HT [8]. There is no consensus, 
which dose constrains are crucial to reduce HT, moreover 
available data are based on small groups studies, what limit 
its application to daily clinic. Many investigators suggest that 
low and medium doses ≤ V20 may be most relevant for HT in 
CRT of pelvic region [47, 49–51]. Mell et al. found that pelvic 
BM-V10, BM-V20 was associated with ≥ grade 2 leukopenia 
(BM-V10 additionally with neutropenia) in CRT for cervical 
cancer [47]. In another paper Mell et al. showed that Pelvic 
BM-V5-V20 was correlated with decreased white blood cell 
count (WBC) and absolute neutrophils count (ANC) nadirs 
in CRT for anal cancer [49]. Albuquerque et al. suggested 
that only BM-V20 was correlated with grade 2 HT in CRT for 
cervical cancer patients [50]. Similarly, Rose et al. concluded 
that BM-V10 ≥ 95% and BM-V20 > 76% dose constrains 
predict grade ≥ 3 leukopenia in CRT for cervical cancer [51]. 
Contrary to those findings, Klopp et al. in analysis of HT in 
RTOG 0418 trial indicated that BM-V40 was associated with 
occurrence of grade 2 HT in CRT for cervical cancer [52]. In 
CRT for rectal cancer Yang et al. showed that patients with 
coxal (bilateral ilium, ischium and pubic) BM-V45 and sacral 
BM-V45 experienced lower WBC and ANC nadirs [53]. In 
another paper, Wan et al. indicated that lumbosacral BM-
V40 predicted grade ≤ 2 HT in CRT for rectal cancer [54]. 
In the study including 100 women, Chang et al. noted that 
IMRT was superior to 3-D RT in medium and high doses 
(BM-V20, BM-V30, BM-V40) and mean BM dose [55]. Those 
parameters were most significant for HT in CRT for cervical 
cancer [55]. Noteworthy RapidArc plans presented higher 
mean BM dose, BM-V10 and BM-V40 than IMRT [55]. In the 
biggest study including 121 chemonaïve prostate cancer 
patients, Sini et al. demonstrated that BM-V40 predicted 
acute grade 3 and late grade 2 lymphopenia [24]. Analysis 
by Zhu et al. supported thesis of significant role of multiple 
doses-volume parameters in BM [56]. BM-V20, V30 and V40 
were found to predict HT (V10 border significance) [56]. The 
researchers estimated that every 1 Gy of BM mean dose 
decreased ln (ANC) by 9.6/mL per week [56]. Franco et al. 
confirmed importance of BM-V20 for WBC nadir and lower 
pelvis BM-V40 for grade 3 acute HT [58]. Multiplicity of dose 
volume parameters connected with HT may lead to con-
clusion that bone marrow function is affected by both low 
and high doses. Moreover mean bone marrow dose may be 
significant for HT in CRT of cervical and anal cancer) [56, 57]. 
Bazan et al. suggest that mean BM dose 22,5Gy and 25Gy 
predicted 5 and 10% risk of HT [57]. In view of above papers, 
BM acts as parallel organ and whole spectrum of doses may 
be significant [57].
Many other risk factors such as body mass index, gender, 
smoking, complete blood count (CBC) at baseline, cancer 
clinical stage were evaluated as predictors for HT, with no 
consistent conclusions in different studies. Baseline CBC pa-
rameters seem to be independent predictors for HT [24, 49]. 
Although association of gender, body mass index (BMI) with 
HT was shown, it might be, in fact, result of different shape/
volume of pelvis [49, 73]. It may influence dose distribution 
in pelvic BM [73].
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Subregions bone marrow sparing RT 
Large pelvic bone marrow volume and shape surroun-
ding pelvic organs make it technically challenging to reduce 
dose in the whole pelvic BM. Identifying the most clinically 
relevant regions of BM may be a solution. It was shown 
that IMRT allows to reduce dose to active bone marrow 
effectively without compromising the coverage of target 
and organs at risk (OAR) [74]. Mell et al. divided pelvic bone 
marrow to lower pelvis (LP) (comprising ischium, pubic and 
proximal femora) lumbosacral spine (LSS) and ilium (IL) [47]. 
They found that LSS-V20, LP- V10 and LP-V20 correlated 
with grade 2 HT for CRT of cervical cancer [47]. LSS-V5 to 
20 was associated with ANC and WBC nadirs in anal cancer 
patients [49]. Yang et al. (as described above) showed that 
specific regions of BM were associated with acute HT [53]. 
Sini et al. proposed a model for 1-year lymphopenia with 
iliac BM dose metrics [24]. The subvolumes of BM based 
on bone anatomy still remain large. Further attempts were 
made to reduce volume of delineated BM to only BMact. 
BMact cannot be distinguished from BMinact on basis of 
computer tomography [75]. Promising results were shown 
in studies concerning functional imaging such as PET, ma-
gnetic resonance imaging (MRI) and spectroscopy (SPECT) 
[8, 61, 74, 76–79]. Restriction of delineated volume of BM, 
when entered as constraint for IMRT plan, result in significant 
reduction of dose in BMact, irrespective of technique used 
for delineation of BMact (MRI, SPECT, PET) [80–82].
MRI delineation of active bone marrow bases on diffe-
rent chemical and cellular composition of red BMact and 
yellow BMinact [83]. BMact made of fat-40%, water-40% and 
protein-20% exhibits on T1-weighted images as region of 
signal intensity equal or lower than that of muscles [80, 83]. 
BMinact consists of fat-80%, water-15% and protein-5% and 
is hiperintense on T1-weighted sequence of MRI [80, 83]. 
V5-BMact identified on MRI was correlated with decreased 
WBC, ANC, platelets count (PLT) nadirs in CRT for rectal 
cancer [76]. Multivariate analysis of data of CRT in gastric 
cancer revealed correlation between dose volume metrics 
of BMact and nadirs of CBC (increased V20-BMact resulted 
in decreased WBC and ANC nadirs) [61]. As MRI is routinely 
administered before radiotherapy of most cancers in pelvis, 
it is a valuable tool to delineate BMact [9, 59, 84]. The two 
main disadvantages of delineation based on T1 MRI are 
that it is rather subjective (not based on any parametrical 
values) and it is time consuming due to the fact that it is 
performed manually [61, 76]. Recently published analysis 
on semi-automated BMact segmentation on basis of Dixon 
sequence of MRI may be the solution, but must be evalu-
ated in more details [75]. Fat composition changes were 
observed after radiotherapy which were correlated with 
CBC parameters [85].
Another approach to distinguish BMact and BMinact 
is application of (18)F-fluorodeoxyglucose positron emis-
sion tomography (FDG-PET), (18)F-fluorothymidine positron 
emission tomography (FLT-PET) and spectroscopy [86, 87]. 
Regions of BM with standard uptake value (SUV) greater 
than patient’s mean were proposed to represent BMact and 
can be used as constrain for IMRT plan [8, 77, 88]. Wyss et al. 
compared feasibility of FDG-PET and FLT-PET and concluded 
that although FLT-PET had minor individual variation, both 
methods findings were consistent [78]. Rose et al. found 
the correlation between mean dose in BMact delineated 
on basis of FDG-PET before CRT for cervical cancer and 
log (WBC) nadirs, log (ANC) nadirs, PLT nadirs [77]. BMact-
-V10, BMact-V20, BMact-V30 were associated with decre-
ased log (WBC), however no correlations were shown for 
BMinact [77]. Elicin et al. observed reduction of volume of 
FDG-PET based BMact after CRT for cervical cancer [79]. It 
was correlated with V30-BMact and reduction in WBC [79]. 
Various dose volume parameters of BMtot and BMact cor-
related with late HT in Elicin’s study [79]. McGuire et al. 
observed FLT-PET BMact volume during and after CRT for 
cervical cancer [82]. Authors indicated that even the dose 
of 4Gy reduced SUV of BMact by 50% and was correlated 
with the time of occurrence of acute HT [82]. Doses greater 
than 35Gy caused chronic suppression of BM (measured as 
reduction of SUV) [82]. Recently published first multicenter 
trial by Mell et al. has tried to compare PET BMact sparing 
IMRT and whole pelvic BMtot sparing IMRT [8]. Although 
authors have observed reduced HT in PET BMact sparing 
group, they have reported that in this group, dose volume 
parameters for the whole pelvic BMtot were significantly 
lower as compared to “without PET” BMtot sparing group 
[8]. They have admitted that the mechanism of reduced 
toxicity in PET BMact sparing group is not fully explained 
and can indeed be the consequence of dose reduction in 
pelvic BMtot rather than BMact [8].
The indirect proof of relevance of PET based deline-
ation of BM may be a decreased SUV in BM regions after 
irradiation in FDG-PET imaging [79, 89, 90]. BM suppression 
(measured as reduction of SUV) correlated with different 
CBC values [79, 89]. Further improvement of BM sparing 
RT can be achieved with the implementation of proton 
beams [91]. Dinges et al. created alternative proton beam 
plans for IMRT FLT-PET BM sparing RT and showed dosi-
metric advantage in the whole dose range; at least: 23% 
(for V5-BMact), 37% (for V10-BMact), 41% (for V20-BMact) 
and 39% (for V40-BMact) [91]. 
Conclusion
In view of the recent studies, hosts own immunity plays 
a key role in cancer survival and efficiency of cancer tre-
atment. Although no mature data is available, in view of 
published studies, effort to reduce immunosuppressive 
effect of cancer treatment, may gain in significance. BMS-
-RT is a promising approach which leads to the reduction 
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of HT. Greater number of studies confirm the correlation 
between dose-volume parameters of BMtot and HT than 
the correlation of dose-volume parameters and BMact and 
HT. However, it is technically more effective to reduce a dose 
to smaller volume such as BMact. Dose-volume parame-
ters of BM considered as clinically relevant differ in studies, 
some have borderline significance. Further studies on large 
cohorts and metaanalysis of above papers are necessary. 
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